Aktieanalys

Active Biotech Q4 2022: Laquinimod Ready for Phase II - Redeye

{newsItem.title}

Redeye Publicerad: 09 Feb 2023 12:22

Redeye comments on Active Biotech's report for the fourth quarter and discusses events and the status of the clinical programs.

Länk till analysen i sin helhet: https://www.redeye.se/research/874681/active-biotech-q4-2022-laquinimod-ready-for-phase-ii?utm_source=finwire&utm_medium=RSS

Nyheter om Active Biotech

Läses av andra just nu

Om aktien Active Biotech

Senaste nytt